The oncology consultancy Company using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions has announced that its National Institute for Health Research (NIHR) Invention for Innovation (i4i) programme funded observational clinical study (the “PARTNER” study), has this week received both ethics committee and Health Research Authority (HRA) approval. It is now expected that the study will commence early ....
15 Dec 2020
Groundwork in place for early 2021 launch of grant funded study of precision dosing tool in prostate cancer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Groundwork in place for early 2021 launch of grant funded study of precision dosing tool in prostate cancer
Physiomics Plc (PYC:LON) | 1.3 0 13.0% | Mkt Cap: 1.76m
- Published:
15 Dec 2020 -
Author:
Derren Nathan -
Pages:
8
The oncology consultancy Company using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions has announced that its National Institute for Health Research (NIHR) Invention for Innovation (i4i) programme funded observational clinical study (the “PARTNER” study), has this week received both ethics committee and Health Research Authority (HRA) approval. It is now expected that the study will commence early ....